AG
IMNP

Advisor Group’s Immune Pharmaceuticals Inc. IMNP Stock Holding History

Advisor Group’s Portfolio IMNP Stock Details IMNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-3,750
Closed -$1K – 5167
2018
Q1 		$1K Hold
3,750
– – ﹤0.01% 4910
2017
Q4 		$2K Hold
3,750
– – ﹤0.01% 4757
2017
Q3 		$6K Hold
3,750
– – ﹤0.01% 4241
2017
Q2 		$12K Hold
3,750
– – ﹤0.01% 3843
2017
Q1 		$11K Hold
3,750
– – ﹤0.01% 3757
2016
Q4 		$14K Buy
+3,750
New +$15.4K ﹤0.01% 3472

Other funds holding IMNP

CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Advisor Group's IMNP Position: Q2 2018 in Review

Advisor Group sold out of Immune Pharmaceuticals Inc. (IMNP) in Q2 2018, closing a stake of 3,750 shares — an estimated $1K sold.

Advisor Group first reported a position in IMNP in Q4 2016 and held it in 6 quarters. The position peaked at $14K in Q4 2016. 13 funds tracked by Wall St. Rank hold IMNP as of Q2 2018.

  • Advisor Group reported no remaining Immune Pharmaceuticals Inc. position as of Q2 2018 after selling out during the quarter.
  • Advisor Group sold 3,750 Immune Pharmaceuticals Inc. shares in Q2 2018, an estimated $1K.
  • Advisor Group first reported a position in Immune Pharmaceuticals Inc. in Q4 2016 and held it in 6 quarters.
  • Advisor Group's Immune Pharmaceuticals Inc. position peaked at $14K in Q4 2016.
  • 13 funds tracked by Wall St. Rank held Immune Pharmaceuticals Inc. as of Q2 2018.

Based on Advisor Group's 13F filing for Q2 2018, filed 13 Aug 2018.